International Coalition to Eliminate Hepatitis B (ICE-HBV) Scientific Strategy Consultation

HBV Forum 2017

Peter Revill
Doherty Institute
Australia



Consultation Goals

- Share updates on ICE-HBV
- Present preliminary scientific agenda
- Receive feedback from industry and regulators
- Discuss potential new collaborations




ICE-HBV AIM

 Safe, affordable, scalable and effective cure, available to all persons living with CHB.

VISION

 International, independent, researchbased and patient-centered forum





Governing Board

- Honorary President Frank Chisari
- Chair Peter Revill
- Co-Chair Fabien Zoulim
- Other Members
 - Massimo Levrero
 - Stephen Locarnini
 - Jake Liang
 - John Tavis
 - Ex-Officio: Program Manager, Capucine Penicaud

To be expanded to include representatives from Asia, Africa and Latin America, as well as key organisations and patient forums.



Key Stakeholders Group advises our researchers

- Chairs: Veronica Miller, Ulla Protzer, Tim Block.
- Stakeholders

ANRS; ASHM; Asian Liver Centre; Bill and Melinda Gates Foundation (Beijing); Biomed Central/WHO CC; CEVHAP; NCHHSTP, CDC; DZIF; Hepatitis Australia; Hepatitis B Foundation; Hepatitis Education Project; Inno Community Development; MRC Unit – The Gambia; NIAID; Pasteur Institute/International Network of Pasteur Institutes; The Forum for Collaborative Research; The World Hepatitis Alliance; World Indigenous Peoples' Conference on Viral Hepatitis; WHO; WHO Collaborating Centre for Viral Hepatitis; Yellow Warriors.



Senior Strategic Advisors

- Professor Raymond Schinazi
- Professor Christian Brechot
- + more soon



Working Groups

Maura Dandri & Haitao Guo
12 members, 4 continents

Virology Immunology

Clinical Studies Co-Chairs

Adam Gehring & Robert Thimme, 12 members, 3 continents

Jianming Hu & Fengmin Lu,
18 members, 5 continents

Harry Janssen, Pietro Lampertico & Seng Gee Lim



What are we doing?

- Producing a joint position paper on what will be needed to achieve HBV cure, similar to papers published in the HIV field (Deeks et al. Nat. Med. 2016).
- Engagement of basic scientists, clinicians, public health, research organisations, industry and patient forums
- Projects:
 - cccDNA assay standardization
 - Mathematical modelling
 - Future: POC diagnostics/assays
 - Other harmonisation studies



Research Priorities

 Extensive brainstorming & prioritization process among Working Group members

- Prioritized the main areas for HBV cure research in
 - Virology
 - Immunology
 - Tools



Concerted harmonization efforts of HBV cccDNA quantification







(HBV meeting, Washington DC, Sep 2017)

endorsed by:



Hamburg (M. Dandri lab)
Lyon (F. Zoulim lab)
Indianapolis (H. Guo lab)
Munich (Protzer lab)
Heidelberg (S. Urban lab)
Foster City (Gilead)

Jianming Hu (US)
Peter Revill (AUS)
Stephen Locarnini (AUS)
Jake Liang (US)
Koichi Watashi (Japan)
Hung-Chih Yang's lab (Taiwan)
Dieter Glebe (Germany)
Anna Kramvis (Africa)
Sofia Perez-del-Pulgar / X. Forns (Spain)

•••



We can facilitate new standardisation projects

- Serum markers (RNA, HBcrAg)
- Chromatin (ChIP) assay
- Role of HBc and HBx in cccDNA activity and maintenance
- Cell culture models (iPSCs)
- New in vivo models
- Standardized HBV peptide libraries and tetramers
- POC diagnostics

Let's work together to make this happen!



Acknowledgements

ICE-HBV Governing Board

Frank Chisari

Peter Revill

Fabien Zoulim

Massimo Levrero

Stephen Locarnini

Jake Liang

John Tavis

Capucine Penicaud (Ex-Officio)

ICE-HBV Scientific Working Groups & Stakeholders Group













